Is RGEN a good stock to buy? We came across a bullish thesis on Repligen Corporation on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on RGEN. Repligen Corporation’s share was trading at $136.44 as of June 30th. RGEN’s trailing and forward P/E were 149.86 and 68.97 respectively according to Yahoo Finance.
Copyright: katrintimoff / 123RF Stock Photo
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America and internationally. RGEN is presented as an attractive opportunity to capitalize on elevated market volatility through the sale of November $110 cash-secured puts, allowing investors to collect substantial premium while underwriting a strike that sits below key technical support levels and well beneath analysts’ valuation expectations.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The opportunity emerged after the stock experienced an unusually sharp 22% swing within three weeks, rallying to $126 following strong first-quarter 2026 results, falling to $102.87 during a broad selloff in high-multiple life sciences stocks, and quickly recovering to around $125.
This heightened volatility pushed implied volatility on the November $110 puts to roughly 57%, creating what is viewed as an excessive fear premium for a profitable, cash-rich company with improving fundamentals. Repligen reported first-quarter revenue of $194 million, up 15% year over year on a reported basis and 11% organically, while GAAP EPS increased 50% and adjusted EPS rose 23%. Management also raised its full-year adjusted EPS guidance to $1.97–$2.05 and reaffirmed expectations for 9%–13% organic revenue growth, implying annual revenue of $810–$840 million.
Growth was supported by strong Process Analytics performance, expanding demand from emerging biotechnology customers, and double-digit consumables growth, suggesting the inventory correction that weighed on results during 2023 and 2024 has largely ended. The $110 strike also provides a considerable margin of safety, sitting around 15% below the lowest analyst price target of approximately $130, while the average analyst target of roughly $167 implies meaningful upside from current levels.
Overall, the elevated option premium, improving operating momentum, strong balance sheet with approximately $785 million in cash, and favorable long-term outlook create a compelling bullish risk-reward profile for investors seeking to generate income while potentially acquiring shares at an attractive valuation.
Previously, we covered a bullish thesis on Thermo Fisher Scientific Inc. (TMO) by Kontra in October 2024, which highlighted the company’s position as a quality compounder with durable growth driven by its leadership in life sciences tools and disciplined capital allocation. TMO’s stock price has depreciated by approximately 16.67% since our coverage. OppCost shares a similar view but emphasizes on Repligen Corporation’s improving fundamentals and a volatility-driven put-selling opportunity.
Repligen Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held RGEN at the end of the first quarter which was 43 in the previous quarter. While we acknowledge the risk and potential of RGEN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RGEN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
